Resistant hypertension is a state characterized by sustained hypertension despite adherence to the standard pharmacological treatment with beta-blockers, calcium channel blockers, diuretics, and ACE inhibitors or ARBs. Resistant hypertension is a problem now in cardiovascular medicine because of its association with increased stroke, heart failure, kidney disease, and vision loss. Renal denervation (RDN) is an invasive treatment strategy for patients with hypertension who are unresponsive to pharmacological therapy. Therefore, this procedure has become a feasible alternative, and this review explores and compares with other possible novel options. RDN's mechanisms, efficacy, safety, and future directions are also discussed. No serious side effects have been reported in the short-term use of RDN, but some of the complications include renal stenosis and hypertensive urgencies in the long term. Despite this, RDN can benefit patients who are non-compliant with medications or are intolerant. However, it should also be pointed out that some clinical studies have not given consistent results. RDN may be employed as secondary therapy as opposed to the primary line of treatment in resistant hypertension. Subsequent studies should assess the technique's durability and establish customized approaches to deliver RDN safely while determining specific biomarkers that can predict patients' outcomes.
Keywords: Clinical trials; Hypertension; Mineralocorticoid receptor antagonists; Novel; Renal denervation.
© 2024. The Author(s).